Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

News

2019 - 07 - 22

Dermatix(R) Unveils New Product Breakthrough for Acne Scarring Solution

23 July 2019, Kula Lumpur - Dermatix®, a brand of A.Menarini Singapore Pte.Ltd has just launched its new acne scar care, Dermatix® Acne Scar. Formulating with Niacinamide (Vitamin B3), Alpha Hydroxy Acids (AHAs) and antioxidants, it delivers a gentle exfoliation to repair acne scars for an overall more even skin tone. Created by top derma experts in Europe, it is now available in Malaysia -the Asia Pacific's first country in launching the product.

 

"Dermatix® Acne Scar targets specific acne's after-effects, such as scars and dark spots, struggled by most people in their teens and early 20s. Bringing skin-savvy ingredients, we simplify the reducing treatment with a clinically-proven silicone gel, that is easy to apply for all skin types," said Joel J. Calleja, General Manager of A. Menarini Singapore Pte. Ltd.

 

This is a win for Asian skin, that is prone to sensitivity and scarring. Experts said, Asian skin is genetically predisposed to scar more easily, as it has a thinner outermost layer of skin. With an increased amount of melanin, Asian skin also tends to have more issues with acne-scars and post-inflammatory hyperpigmentation.

 

Stimulating new skin cells and collagen production, Dermatix® Acne Scar is enriched with ActivGCS Beauty Enhancers, consisting of snail slime extract and Hyaluronic Acid to boost the skin's repairing process. Combating post-acne skin discoloration, the treatment gel contains Niacinamide (Vitamin B3) to reduce hyperpigmentation. Additionally, Zinc Gluconate helps to regulate oil level in the skin.

 

The treatment starts by applying Dermatix® Acne Scar once in the morning and before bedtime over affected areas. "Massage a pea-sized amount of the gel to get it absorbed perfectly in your skin, but ensure your acne is completely healed before starting on the treatment. Study shown that 72% of users noticed their acne scars getting less visible after using Dermatix® Acne Scar for 4 weeks1," said Joel.

 

Since the brand's Malaysia launch in 2009, Dermatix® has led the market in the scar category, performed extremely well with the latest award as Guardian Malaysia's Most Voted Brand (MVB) for three consecutive years since 2016 and Winner of Malaysia Health & Wellness Award in 2017. Dermatix® Acne Scar is now available at leading pharmacies nationwide. For more information, visit dermatix.com.my.

 

1 Study of efficacy and tolerance of a treatment against acne scars. 07 August 2018 (Data on File)
 

If you'd like to know more about Menarini, feel free to download our PDF files here.